S27 - General Neurology: Improving Neurologic Care and the Impact of Therapeutics
| Event Time: | Tuesday May 7, 2019 1:00 pm to 3:00 pm |
| Topic(s): | General Neurology |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Dural Venous Sinus Stenting for Idiopathic Intracranial Hypertension: An Updated Review and The Comprehensive Meta-analysis |
Disclosure: Dr. Leishangthem has nothing to disclose.
|
| 1:00 PM | 002 | Risk of Thrombotic Events after Exposure to Intravenous Immunoglobulin or Plasma Exchange for Treatment of Neurologic Disease |
Disclosure: Dr. Jin has nothing to disclose.
|
| 1:00 PM | 003 | EXPLORE: A prospective, multinational natural history study of acute hepatic porphyria patients with recurrent attacks |
Disclosure: Dr. Naik has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alnylam.
|
| 1:00 PM | 004 | Clinical Characteristics of the First 500 Subjects in the Adult Hydrocephalus Clinical Research Network Registry |
Disclosure: Dr. Williams has nothing to disclose.
|
| 1:00 PM | 005 | Reality or Myth: Serotonin Syndrome in Migraineurs with Triptan Use |
Disclosure: Dr. Kerr has nothing to disclose.
|
| 1:00 PM | 006 | Pregnancies in Women with Multiple Sclerosis: Perception of High Risk Among Health Care Providers. Interim Data from PREG-MS Cohort |
Disclosure: Dr. Manieri has nothing to disclose.
|
| 1:00 PM | 007 | Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial |
Disclosure: Dr. Ajroud-Driss has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alnylam, Biogen, Avexis, Akcea.
|
| 1:00 PM | 008 | Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update |
Disclosure: Dr. Brannagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grifols, Ionis, Alnylam, and CSL Behring. Dr. Brannagan has received research support from Ionis, Alnyalm, Viromed, Catalyst, Pharnext, Novartis, Grifols.
|
| 1:00 PM | 009 | Association of Phosphorylated Neurofilament Heavy Chain (pNF-H) Levels With Motor Function Achievement in Individuals With Spinal Muscular Atrophy (SMA) Treated With Nusinersen |
Disclosure: Dr. Sumner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consultant to AveXis, Biogen, Cytokinetics, Genentech, Pfizer, PTC Therapeutics, Roche; scientific advisory boards for CureSMA, MDA, Packard Center for ALS research, SMA Foundation. Dr. Sumner has received personal compensation in an editorial capacity for Associate editor for the Journal of Clinical Investigation. Co-editor of book: Spinal Muscular Atrophy: Disease Mechanisms and Therapy (2017).
|